The phase 3 FORTITUDE-101 trial, conducted with the support of Zai Lab, has been evaluating bemarituzumab plus mFOLFOX6 ...

Bemarituzumab targets FGFR2b, which has been found to be overexpressed in approximately 30% of patients with non-HER2 positive gastric cancer.

The latest advancements in upper gastrointestinal (GI) cancer treatment include early detection tools, immunotherapy, targeted therapies, and surgery techniques.

The majority of patients were postmenopausal with hormone receptor–positive and human epidermal growth factor receptor 2 (HER2)–negative, invasive ductal carcinoma. The median tumor size was 1.1 cm ...